IP-Fälle und Artikel

How to mitigate the risk of central revocation: want to avoid committing to a unitary patent? Here’s how to say “it’s not UPC, it’s me”

The Unified Patent Court (UPC) can be a valuable tool for patent proprietors. A shiny new unitary patent, unlike a classic European patent granted by the European Patent Office (EPO), provides uniform protection rather than a collection of national patent…
Kara Richards
Kara Richards
Technical Assistant
How to mitigate the risk of central revocation: want to avoid committing to a unitary patent? Here’s how to say “it’s not UPC, it’s me”

Patenting trends in generative AI: LLMs, filings and the race for protection

Generative AI (GenAI) is an artificial intelligence technique used to create original content. It involves training a model on a very large dataset, which is then queried to generate new content by identifying patterns in the source material. Such models…
Alan Boyd
Alan Boyd
Partner, Patent Attorney
Jennifer Harvey
Jennifer Harvey
Technical Assistant
Patenting trends in generative AI: LLMs, filings and the race for protection

Space-based quantum key distribution: patenting secure communications

Quantum key distribution (QKD) is one of the most promising approaches to secure communications, providing assurance that no-one has been listening in. Fibre-optic cables are generally unsuited for QKD over long distances, however, satellite relay provides a potential solution and…
Ben Hunter
Ben Hunter
Senior Associate, Patent Attorney
Space-based quantum key distribution: patenting secure communications

The threshold of synergy: when a combination becomes more than a mere aggregation before the UPC

Two recent decisions from the Unified Patent Court (UPC), Promosome v BioNTech/Pfizer and Maxell v Samsung, shed light on how the UPC evaluates the inventive step of claims containing multiple distinguishing features. While the UPC has not expressly adopted the…
Nigel Lee
Nigel Lee
Associate, Patent Attorney
The threshold of synergy: when a combination becomes more than a mere aggregation before the UPC

UK High Court refines “product” meaning: distinction between a medicinal product and the “product” for SPC protection

Accord v Novartis provides important guidance on the distinction between the medicinal product that receives regulatory approval and the “product” for which supplementary protection certificate (SPC) protection is available before the UK Courts.
Oliver Cartwright
Oliver Cartwright
Associate, Patent Attorney
UK High Court refines “product” meaning: distinction between a medicinal product and the “product” for SPC protection
Webinars & Videos